The red cell transfusion trigger: has a sin of commission now become a sin of omission?

被引:55
作者
Valeri, CR
Crowley, JP
Loscalzo, J
机构
[1] Boston Univ, Sch Med, USN, Blood Res Lab, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA
[3] Boston Med Ctr, Evans Dept Med, Boston, MA USA
[4] Boston Med Ctr, Whitaker Cardiovasc Inst, Boston, MA USA
[5] Brown Univ, Sch Med, Rhode Isl Hosp, Dept Med, Providence, RI 02912 USA
关键词
D O I
10.1046/j.1537-2995.1998.38698326341.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The benefits of a Hct range of 30 to 35 percent include improved oxygen delivery and enhanced hemostasis, which help minimize complications in patients at high risk for ischemia and perioperative nonsurgical bleeding. In these settings, the conservative transfusion practice of using a lower Hct range should be replaced with a more aggressive approach. The known risks of blood transfusion would appear to be sufficiently low and the benefits sufficiently high to justify maintaining a Hct of at least 30 percent. An even higher Hct, of 35 percent, may be desirable in patients who have over cardiopulmonary disease or who are at high risk for myocardial ischemia. Many retrospective studies have been conducted to persuade us that a conservative transfusion trigger is a safe and prudent practice, but retrospective studies are not what we need. What we need is a series of well-designed, prospective, randomized trials to evaluate the impact of a more aggressive transfusion policy on perioperative mortality, morbidity, and nonsurgical bleeding in patients with known cardiopulmonary disease or who are at high risk for myocardial and cerebrovascular ischemia.
引用
收藏
页码:602 / 610
页数:9
相关论文
共 100 条
[1]   EFFECTS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN AND CORRECTION OF ANEMIA ON PLATELET-FUNCTION IN HEMODIALYSIS-PATIENTS [J].
AKIZAWA, T ;
KINUGASA, E ;
KITAOKA, T ;
KOSHIKAWA, S .
NEPHRON, 1991, 58 (04) :400-406
[2]  
ALKHAMIS TM, 1990, BLOOD, V75, P1568
[3]  
ALKHAMIS TM, 1987, ASAIO T, V10, P636
[4]   HEMATOCRIT AND BLEEDING-TIME - AN UPDATE [J].
ANAND, A ;
FEFFER, SE .
SOUTHERN MEDICAL JOURNAL, 1994, 87 (03) :299-301
[5]   ENDOTHELIUM-DERIVED RELAXING FACTOR IS IMPORTANT IN MEDIATING THE HIGH-OUTPUT STATE IN CHRONIC SEVERE ANEMIA [J].
ANAND, IS ;
CHANDRASHEKHAR, Y ;
WANDER, GS ;
CHAWLA, LS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 25 (06) :1402-1407
[6]   THE INCIDENCE OF PERIOPERATIVE MYOCARDIAL-INFARCTION IN MEN UNDERGOING NONCARDIAC SURGERY [J].
ASHTON, CM ;
PETERSEN, NJ ;
WRAY, NP ;
KIEFE, CI ;
DUNN, JK ;
WU, L ;
THOMAS, JM .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (07) :504-510
[7]   ENDOTHELIUM-DEPENDENT INHIBITION OF PLATELET-AGGREGATION [J].
AZUMA, H ;
ISHIKAWA, M ;
SEKIZAKI, S .
BRITISH JOURNAL OF PHARMACOLOGY, 1986, 88 (02) :411-415
[8]  
BELL DN, 1990, THROMB HAEMOSTASIS, V63, P112
[9]  
BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700
[10]  
Birchard GF, 1997, AM ZOOL, V37, P65